I'm the first to admit that following the Cytogen IP has been difficult and almost too esoteric for me. I mean, take a look again at this sentence:
The product candidate uses DOTA-based bifunctional chelant technology to radiolabel Cytogen's proprietary monoclonal antibody to prostate-specific membrane antigen (PSMA) with a therapeutic radionuclide
Notwithstanding the jargon, there is a lot of convoluted IP tied up there.
I find it interesting that Cytogen retained rights to this little estate carved out of the PSMA kingdom:
The 7E11 antibody was excluded from the PSMA technology licensed to the PSMA Development Company LLC, the Company's joint venture for PSMA product development. Consequently, the joint venture is not involved in this development initiative.
It makes me wonder if Cytogen felt this antibody had so much promise that it deserved to be retained for itself. It also makes me wonder if prospects for the PSMA Development Company (the 50/50 Cytogen/Progenics JV) are being undermined by Cytogen.
I don't have a clue what this means from an investment perspective, but I am going to dig a little deeper.
Urche
Market Data 
Markets 
AI
